RGEN - Repligen Corporation logo

Repligen Corporation

RGEN

Repligen Corporation develops bioprocessing technologies for manufacturing biological drugs. Its products include chromatography systems, filtration devices, and analytics tools, catering to biopharmaceutical companies, research labs, and contract manufacturers worldwide.

⚕️ Healthcare NASDAQ Listed 1990 $ USD
$1,000 invested 30 years ago →$117,949today

Score Overview

1 Year
Score
Net Growth-124.14%
Net TrendShrank
Net Income Consistency—
Rev Growth9.12%
Rev TrendGrew
Revenue Consistency—
5 Years
Score4.0
Net Growth-109.20%
Net Trend40%
Net Income Consistency—
Rev Growth20.14%
Rev Trend60%
Revenue Consistency—
10 Years
Score
Net Growth-201.05%
Net Trend60%
Net Income Consistency
Rev Growth7x
Rev Trend80%
Revenue Consistency
20 Years
Score5.0
Net Growth-11x
Net Trend59%
Net Income Consistency
Rev Growth57x
Rev Trend78%
Revenue Consistency
30 Years
Score
Net Growth-21x
Net Trend48%
Net Income Consistency
Rev Growth212x
Rev Trend75%
Revenue Consistency
All Time
Score
Net Growth-107.09%
Net Trend48%
Net Income Consistency
Rev Growth106x
Rev Trend68%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Repligen Corporation has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • RGEN

2001: 98.4% · 2020: 25.6% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 162.18—
1 Year2025-11-17
$ 149.008.85%
5 Years2021-11-17
$ 277.48-41.55%
10 Years2016-11-17
$ 33.04390.86%
20 Years2006-11-17
$ 2.9554x
30 Years1996-11-15
$ 1.38117x
All Time1990-03-26
$ 11.5014x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 805M-$ 11M$ 862M
2025$ 738M$ 48M$ 767M
2024$ 634M-$ 25M$ 757M
2023$ 638M$ 41M$ 751M
2022$ 801M$ 185M$ 623M
2021$ 670M$ 128M$ 603M
2020$ 366M$ 59M$ 717M
2019$ 270M$ 21M$ 528M
2018$ 194M$ 16M$ 193M
2017$ 141M$ 28M$ 173M
2016$ 104M$ 11M$ 141M
2015$ 83M$ 9M$ 73M
2014$ 63M$ 8M$ 62M
2013$ 68M$ 16M$ 61M
2012$ 62M$ 14M$ 40M
2011$ 26M
2010$ 27M$ 49M
2009$ 20M-$ 4M$ 53M
2008$ 29M$ 5M$ 48M
2007$ 19M$ 37M$ 49M
2006$ 14M-$ 889.26K$ 22M
2005$ 12M$ 696.86K$ 18M
2004$ 9M-$ 2M$ 17M
2003$ 6M-$ 9M$ 13M
2002$ 7M-$ 4M$ 11M
2001$ 4M-$ 4M$ 20M
2000$ 2M-$ 5M$ 23M
1999$ 3M-$ 3M$ 34M
1998$ 2M-$ 2M$ 3M
1997$ 2M-$ 800K$ 3M
1996$ 3M-$ 500K$ 4M
1995$ 10M-$ 11M$ 3M
1994$ 16M-$ 32M$ 13M
1993$ 26M-$ 19M$ 18M
1992$ 27M-$ 11M$ 15M
1991$ 11M-$ 12M$ 29M
IPO1990$ 7M-$ 5M$ 40M
RGEN - Repligen Corporation logo

Repligen Corporation fundamental performance

Between 2015 and 2025, revenue grew from $ 83M to $ 738M and net income grew from $ 9M to $ 48M. Revenue increased in 8 of those 10 years; net income in 6.

Between 2005 and 2025, revenue grew from $ 12M to $ 738M and net income grew from $ 696.86K to $ 48M. Revenue increased in 16 of those 20 years; net income in 12.

Repligen Corporation currently holds a 20-year HDB Score of 5.0 out of 10. How the HDB Score is calculated.

Membership

Continue RGEN’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies